Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]MNI-1216 PET Imaging in Alpha-synucleinopathies
NCT06445465Phase 1Completed
- Sponsor
- Invicro
- Start
- Dec 2020
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of aci-12589 in alpha-synucleinopathy, Parkinson's disease (PD), dementia with Lewy bodies (DLB) and 1 more, sponsored by Invicro. Primary endpoint: Volume of distribution at 78 days. Started Dec 2020; status: completed.
02
Drugs
aci-12589
03
Conditions
alpha-synucleinopathyParkinson's disease (PD)dementia with Lewy bodies (DLB)Multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT06445465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06445465.